Insulin resistance and heart diseases: is there a relationship?


Cite item

Full Text

Abstract

We consider the nature of insulin resistance (IR) underlying on development of type 2 diabetes mellitus and metabolic syndrome, and the main cellular and molecular mechanisms of its formation are presented. The paper is dedicated to the pathogenetic link between IR and hypertension, IR importance in the development of diabetic cardiomyopathy. It is emphasized that metformin (Siofor) is the best drug for insulin sensitivity restoration and improvement of prognosis in cardiac patients. The presence of a various cardioprotective effects of metformin facilitates therapy optimization for patients with high risk of cardiovascular disease.

References

  1. An D, Rodrigues B. Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol 2006;291:H1489-H1506.
  2. Bandyopadhyay GK, Yu JG, Ofrecio J, et al. Increased p85/55/50 expression and decreased phosphatidylinositol 3-kinase activity in insulin-resistant human skeletal muscle. Diabetes 2005;54:2351-59.
  3. Barbour LA, Rahman SM, Gurevich I, et al. Increased P85alpha is a potent negative regulator of skeletal muscle insulin signaling and induces in vivo insulin resistance associated with growth hormone excess. J Biol Chem 2005;280;37489-94.
  4. Barbour LA, Shao J, Qiao L, et al. Human placental growth hormone increases expression of p85 regulatory unit of phosphatidylinositol 3-kinase and triggers severe insulin resistance in skeletal muscle. Endocrinonlogy 2004;145:1144-50.
  5. Boubina S, Abel ED. Diabetic cardiomyopathy revisted. Circulation 2007;115:3213-23.
  6. Boubina S, Abel ED. Mithochondrial uncoupling: a key contributor to reduced cardiac efficiency in diabetes. Physiology 2006;21:250-58.
  7. Cornier M-A, Bessesen DH, Gurevich I, et al. Nutritional up-regulation of p85α expression is an early molecular manifestation of insulin resistance. Diabetologia 2006;49:748-54.
  8. Cusi K, Maezono K, Osman A, et al. Insulin resistance differentially affects the PI-3-kinase - and MAP kinase-mediated signaling in human muscle. J Clin Invest 2000;105:31-20.
  9. De Meyts P. The insuline receptor: structure and function. Rev Med Liege 2005;60(5-6), 286-90.
  10. Frittittta L, Youngen Jl, Vignery R, et al. PC-1 content in skeletal muscle of non-obese, non-diabetic subjects: relationship to insulin receptor tyrosine kinase and whole body insulin sensitivity. Diabetologia 1996;39(10)1190-95.
  11. Garvey WT, Maianu L, Zhu Ju-Hong, et al. Evidence for defects in the trafficking and translocation of GLUT4 transporters in skeletal muscle s a cause of human insulin resistance. J Clin Invest 1998;101:2377-86.
  12. Giorgino F, Perini MT, Smith RJ. Specific increase in p85 α expression in response to dexamethazone is associated with inhibition of insulin-like growth factor-1 stimulated phosphatidylinositol 3-kinase activity in cultured muscle cells. J Biol Chem 1997;272:7455-63.
  13. Hansen BC, Shafrir E. Insulin resistance and insulin resistance syndrome. Frontiers in Animal Diabetes Research, 2002.
  14. Kim J, Montagnani M, Kon Koh K, et al. Recirocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006;113:1888-904.
  15. Lamia KA, Peroni OD, Kim Y-B, et al. Increased insulin sensitivity and reduced adiposity in phosphatidylinositol 5-phosphate 4-kinase β-/- mice. Mol Cell Biol 2004;24:5080-87.
  16. Li Y, Soos TJ, Li X, et al. Protein kinase C inhibits insulin signaling by phosphorylation IRS1 at Ser 1101. J Biol Chem 2004;279:45304-07.
  17. Makaryus AN, Akhrass P, McFarlane SJ. Treatment of hypertension in metabolic syndrome: implications of recent clinical trials. 2009;9:229-37.
  18. Nandi A, Kitamura Y, Kahn R, et al. Mouse Models of insulin resistance. Physiol Rev 2004;84:623-47.
  19. Parakhi RA, Ouyang J, Ochs RS. A New Mechanism of Action for Metformin. 2009;23(1):856.
  20. Pessini JE, Saltiel A. Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest 2002;106:165-69.
  21. Peraldi P, Spiegelman BM. Studies of the mechanism of inhibition of insulin signaling by tumor necrosis factor-a. J Endocrinol 1997;155:219-20.
  22. Reaven GM, Laws A. Insulin resistance: The metabolic Syndrome. Humana Press, 1999.
  23. Rhee MK, Umpierrez GE. Improving Insulin Sensitivity: A Review of New Therapies. Clinical Cornerstone 2008;9(Suppl. 2):S28-S38.
  24. Scarpello JHB, Howlett HCS. Metformin therapy and clinical uses. Diabetes Vasc Dis Res 2008;5(1):57-67.
  25. Young J, Mormons-Trabut L, Couzinet B, et al. Type A insulin resistance syndrome revealing a novel lamin. A Mutation Diabetes 2005;54:1873-78.
  26. Zeitler PS. Nadeau Insulin resistance: childhood precursors and adult disease. Humana Press, 2008.
  27. Дедов И.И., Шестакова М.В. Сахарный диабет и артериальная гипертензия. М., 2006. C. 320-329.
  28. http://www.pharmateca.ru/cgi-bin/statyi.pl?sid=2405&mid=1085056570&magid=179

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies